NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
SN BioScience
Hoffmann-La Roche
Incyte Corporation
Incyte Corporation
TransThera Sciences (Nanjing), Inc.
Alliance for Clinical Trials in Oncology
Cyteir Therapeutics, Inc.
Sellas Life Sciences Group
Vincerx Pharma, Inc.
Xencor, Inc.
Cancer Research and Biostatistics Clinical Trials Consortium
TransThera Sciences (Nanjing), Inc.
Exelixis
HiberCell, Inc.
National Cancer Institute (NCI)
Syros Pharmaceuticals
Massachusetts General Hospital
Eastern Cooperative Oncology Group
Fate Therapeutics
Xencor, Inc.
SWOG Cancer Research Network
Xencor, Inc.
Incyte Corporation
Novartis
AbbVie
AbbVie
Incyte Corporation
Gilead Sciences
Institut Bergonié
Incyte Corporation
AstraZeneca
Abramson Cancer Center at Penn Medicine
MedImmune LLC
University of Wisconsin, Madison
Daiichi Sankyo
Swiss Cancer Institute
Pfizer
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
University of Kansas Medical Center
Roswell Park Cancer Institute
Cancer Trials Ireland
Northwestern University
Vanderbilt University Medical Center
Santa Maria Biotherapeutics
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
Fox Chase Cancer Center
Case Comprehensive Cancer Center